Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor.

Insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) recently have been shown to play a physiological role in the female genital system, including the ovarian follicular system. However, little is known about the role of the IGF system in malignant ovarian disease. To assess possible mutual correlations between alterations in circulating IGFBP profiles and tumuor markers in patients with epithelial ovarian cancer, we performed an RIA for IGFBP-2 and IGFBP-3 and a Western ligand blotting (WLB) in serum samples from 20 patients with epithelial ovarian cancer, 10 patients with benign ovarian tumors, and 8 healthy age-matched controls. The epithelial ovarian cancer group had a mean IGFBP-2 level that was 253% (RIA) and 105% (WLB) above that of controls. IGFBP-2 even correlated positively with the highly sensitive serum tumor marker, cancer antigen 125 (CA 125) (r = 0.71, P < 0.001) but not with the less sensitive tumor-associated trypsin inhibitor. In contrast, serum IGFBP-3 (by RIA and WLB) was decreased in patients with ovarian cancer, and IGFBP-3 proteolytic activity was detectable in some of the patients. Neither IGFBP-3 nor IGFBP-3 proteolytic activity correlated with CA 125; but the former correlated inversely, and the latter positively, with tumor-associated trypsin inhibitor. In conclusion, IGFBP-2 levels are high in serum of epithelial ovarian cancer patients, and the increment in serum IGFBP-2 correlates positively with CA 125. Alterations in serum IGFBP-2 levels may therefore, serve as a potential additional marker for ovarian cancer.

[1]  A. Karasik,et al.  Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. , 1996, British Journal of Cancer.

[2]  P. Bang.  Serum proteolysis of IGFBP-3. , 1995, Progress in growth factor research.

[3]  K. Brismar,et al.  Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. , 1994, The Journal of clinical endocrinology and metabolism.

[4]  A. Karasik,et al.  Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. , 1994, The Journal of clinical endocrinology and metabolism.

[5]  M. Papa,et al.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.

[6]  T. Stamey,et al.  Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.

[7]  L. Giudice.  Insulin-like growth factors and ovarian follicular development. , 1992, Endocrine reviews.

[8]  D. Clemmons,et al.  Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. , 1992, The Journal of clinical endocrinology and metabolism.

[9]  D. Yee,et al.  Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. , 1991, Cancer research.

[10]  J. Holly,et al.  The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. , 1991, The Journal of endocrinology.

[11]  D. Peehl,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. , 1991, The Journal of clinical endocrinology and metabolism.

[12]  N. Ling,et al.  Isolation and molecular cloning of insulin-like growth factor-binding protein-6. , 1991, Molecular endocrinology.

[13]  N. Ling,et al.  Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. , 1991, The Journal of biological chemistry.

[14]  L. Giudice,et al.  A simple assay for proteolysis of IGFBP-3. , 1991, The Journal of clinical endocrinology and metabolism.

[15]  M. Binoux,et al.  Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. , 1990, The Journal of clinical endocrinology and metabolism.

[16]  O. Mogensen,et al.  Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. , 1990, Gynecologic oncology.

[17]  O. Mogensen,et al.  Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours. , 1990, British Journal of Cancer.

[18]  O. Mogensen,et al.  CA 125 in the diagnosis of pelvic masses. , 1989, European journal of cancer & clinical oncology.

[19]  M. Binoux,et al.  Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. , 1986, Analytical biochemistry.

[20]  M. Huhtala.  Demonstration of a new acrosin inhibitor in human seminal plasma. , 1984, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[21]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[22]  U. Stenman,et al.  Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. , 1982, The Journal of biological chemistry.